SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule
ARQL 20.000.0%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ahhaha who wrote (169)2/5/1998 1:59:00 AM
From: ahhaha  Read Replies (1) of 399
 
I might have been right in the first place, the science is looking more and more poor:

Let's look at evaluation. Say the company can hold an 80x. Say an expectation of $.10 by 4Q '99 = $8/shr. (about 1/2 of 15). Currently the company is evaluated at 240x on these parameters. Not unusual for a biotech, but is this a biotech or service company? If it's a service company we would be justified in giving it 30x given its royalty angle and fast Wheel. To warrant current price level, it's got to earn $.80! Anyone think I'm all wet? Well, it's not a service company. Really? The company doesn't adjudicate on efficacy of the chemicals it finds, they just take leads and polish them. If they work, the company gets a kickback. Someone else takes the risk. It's all part of the business plan, n'est-ce pas? Service company. Oui,oui.

Now who was ridiculing me for Ponzi Pies in the sky? Not even with diamonds. You could make some money on the street with that at least.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News